Reduction in the number of imported drugs with similar domestic production to 440 items
The head of Iranian Food and Drug Administration said at the opening ceremony of Actoverco’s new factory for the production of solid drugs : “This year, the issuance of production licenses by the Food and Drug Administration will be accelerated.”
Merck’s commitment to continue its presence in Iran
Paolo Carly’s speech, General Manager of German Merck Company in the Middle East and North Africa at the inauguration of the new Actoverco Solid Drug Production Plant (Actoverco 2)
We did not shout a slogan, we acted
The CEO of the Actover Pharmaceutical Group at the opening ceremony of the new Actoverco Solid Drug Production Plant said: “Currently, there are about 3000 people working in the Actover Pharmaceutical Group, 90% of whom are under 40 years old.”
Official opening of the new factory for production of Actoverco solid drugs (Actoverco 2)
According to PHANA, the official opening and operation ceremony of the new Actoverco solid drug production factory was held in Baharestan Industrial Town.
Actoverco’s CEO resigned
According to Actoverco’s Public Relations, Shahram Shini, CEO of Actoverco, has recently resigned.
Another big step of Iran in the production of anti-cancer drugs
The largest factory for the production of anti-cancer drugs in the Middle East, as well as the biotechnology department of the pharmaceutical group, was put into operation in Alborz with the presence of the Minister of Health.
Actoverco received 90.8 million Euros of governmental currency in the first half of this year
The CEO of Actoverco said: “This Company has received about 90 million and 800 thousand Euros of governmental currency in the first 6 months of the year.”
We do not talk, we act
Shini, CEO of Actoverco on the sidelines of ICCU 2018 in a conversation with PHANA: With proper planning, none of the Actoverco’s drugs will not experience a shortage. We have…
With the lifting of sanctions, many announced their readiness to work with “Actoverco
We have a program for production of Rituximab and Bevacizumab drugs for cancer patients, ophthalmologists, etc. These drugs are very expensive due to their high technical knowledge, and from next year, we will also produce the raw materials for these drugs ourselves.
- « Previous
- 1
- …
- 4
- 5
- 6